Spots Global Cancer Trial Database for bcma
Every month we try and update this database with for bcma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma | NCT06429150 | Multiple Myelom... Plasmacytoma | CAR-T cells | 18 Years - 80 Years | Shenzhen Geno-Immune Medical Institute | |
| PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma | NCT05172596 | Multiple Myelom... | PHE885 | 18 Years - | Novartis | |
| Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma | NCT04706936 | Relapsed or Ref... | anti-BCMA CAR-T Cyclophosphamid Fludarabine | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) | NCT04196491 | Multiple Myelom... | bb2121 Fludarabine Cyclophosphamid... Lenalidomide | 18 Years - | Celgene | |
| Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma | NCT04162119 | Multiple Myelom... | BCMA-PD1-CART C... | 14 Years - 80 Years | Chinese PLA General Hospital | |
| Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma | NCT04155749 | Relapsed and Re... | anitocabtagene-... ARC-T Plus Anti... | 18 Years - | Gilead Sciences | |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | NCT06152575 | Multiple Myelom... | Elranatamab Elotuzumab Pomalidomide Dexamethasone Bortezomib Carfilzomib | 18 Years - | Pfizer | |
| a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma | NCT04776330 | Multiple Myelom... Neoplasm, Plasm... Multiple Myelom... | BCMA targeted p... | 18 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | NCT05020236 | Multiple Myelom... | Elranatamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Pfizer | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma | NCT03090659 | Refractory or R... | LCAR-B38M CAR-T... | 18 Years - 80 Years | Nanjing Legend Biotech Co. | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies | NCT02954445 | Leukemia Lymphoma Multiple Myelom... | Anti-BCMA-CAR-t... | 14 Years - 75 Years | Southwest Hospital, China | |
| A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | NCT06215118 | Multiple Myelom... | Elranatamab Iberdomide | 18 Years - | Pfizer | |
| Study of bb2121 in Multiple Myeloma | NCT02658929 | Multiple Myelom... | bb2121 | 18 Years - | Celgene | |
| a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma | NCT04776330 | Multiple Myelom... Neoplasm, Plasm... Multiple Myelom... | BCMA targeted p... | 18 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma | NCT04617704 | Multiple Myelom... | GC012F injectio... | 18 Years - | Shanghai Changzheng Hospital | |
| Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma | NCT03430011 | Multiple Myelom... | JCARH125 JCARH125 + anak... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Study of bb2121 in Multiple Myeloma | NCT02658929 | Multiple Myelom... | bb2121 | 18 Years - | Celgene | |
| Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma | NCT04162119 | Multiple Myelom... | BCMA-PD1-CART C... | 14 Years - 80 Years | Chinese PLA General Hospital | |
| A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | NCT06413498 | Multiple Myelom... | Anitocabtagene ... Cyclophosphamid... Fludarabine Pomalidomide Bortezomib Dexamethasone Daratumumab Carfilzomib | 18 Years - | Gilead Sciences | |
| BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma | NCT04162353 | Multiple Myelom... Refractory Mult... Plasmacytoid; L... | BCMA-CD19 cCAR ... | - | iCell Gene Therapeutics | |
| BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma | NCT04617704 | Multiple Myelom... | GC012F injectio... | 18 Years - | Shanghai Changzheng Hospital | |
| the Safety and Efficacy of SENL103 Autologous T Cell Injection | NCT06067581 | Multiple Myelom... | SENL103 | 18 Years - 75 Years | Hebei Senlang Biotechnology Inc., Ltd. | |
| Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma | NCT03361748 | Multiple Myelom... | bb2121 | 18 Years - | Celgene | |
| A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | NCT05430945 | Relapse Multipl... Refractory Mult... | BCMA Targeted C... | - | Zhejiang University | |
| Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma | NCT04706936 | Relapsed or Ref... | anti-BCMA CAR-T Cyclophosphamid Fludarabine | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| the Safety and Efficacy of SENL103 Autologous T Cell Injection | NCT06067581 | Multiple Myelom... | SENL103 | 18 Years - 75 Years | Hebei Senlang Biotechnology Inc., Ltd. | |
| BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma | NCT04617704 | Multiple Myelom... | GC012F injectio... | 18 Years - | Shanghai Changzheng Hospital | |
| Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma | NCT04155749 | Relapsed and Re... | anitocabtagene-... ARC-T Plus Anti... | 18 Years - | Gilead Sciences | |
| MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb | NCT04649359 | Multiple Myelom... | Elranatamab (PF... | 18 Years - | Pfizer | |
| PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma | NCT05172596 | Multiple Myelom... | PHE885 | 18 Years - | Novartis | |
| A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma | NCT05932290 | Multiple Myelom... | Elranatamab Standard of car... | 18 Years - | Pfizer | |
| A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment | NCT05828511 | Multiple Myelom... | Linvoseltamab | 18 Years - | Regeneron Pharmaceuticals | |
| Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma | NCT04822337 | Multiple Myelom... | Carfilzomib, Le... | 18 Years - | Wake Forest University Health Sciences | |
| MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | NCT05020236 | Multiple Myelom... | Elranatamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Pfizer | |
| BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma | NCT04236011 | Multiple Myelom... | GC012F injectio... | 18 Years - | Shanghai Changzheng Hospital | |
| Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma | NCT03266692 | Multiple Myelom... Multiple Myelom... Refractory Mult... | ACTR087 SEA-BCMA | 18 Years - 80 Years | Cogent Biosciences, Inc. | |
| Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | NCT04272151 | Multiple Myelom... Multiple Myelom... Neoplasm, Plasm... | BCMA CAR-T cell... | 18 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma | NCT04156269 | Multiple Myelom... | BCMA-CS1 cCAR T... | - | iCell Gene Therapeutics | |
| Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma | NCT03448978 | Multiple Myelom... | Descartes-08 Fludarabine Cyclophosphamid... | 18 Years - | Cartesian Therapeutics | |
| A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma | NCT04394650 | Multiple Myelom... | CC-98633 | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| Descartes-11 in Multiple Myeloma | NCT03994705 | Multiple Myelom... | Descartes-11 Fludarabine Cyclophosphamid... | 18 Years - | Cartesian Therapeutics | |
| Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) | NCT06057402 | Multiple Myelom... | Elranatamab | 18 Years - | Pfizer | |
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma | NCT06429150 | Multiple Myelom... Plasmacytoma | CAR-T cells | 18 Years - 80 Years | Shenzhen Geno-Immune Medical Institute | |
| A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | NCT05675449 | Multiple Myelom... | Elranatamab Carfilzomib Maplirpacept | 18 Years - | Pfizer | |
| Study of bb2121 in Multiple Myeloma | NCT02658929 | Multiple Myelom... | bb2121 | 18 Years - | Celgene | |
| BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma | NCT04617704 | Multiple Myelom... | GC012F injectio... | 18 Years - | Shanghai Changzheng Hospital | |
| A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | NCT05675449 | Multiple Myelom... | Elranatamab Carfilzomib Maplirpacept | 18 Years - | Pfizer | |
| A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma | NCT04394650 | Multiple Myelom... | CC-98633 | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma | NCT04271644 | Multiple Myelom... Neoplasm, Plasm... Multiple Myelom... | BCMA CAR-T cell... | 18 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma | NCT04318327 | Multiple Myelom... | PHE885 | 18 Years - | Novartis | |
| Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients | NCT04287660 | Multiple Myelom... | clarithromycin,... | 18 Years - 75 Years | The First Affiliated Hospital of Soochow University | |
| A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment | NCT05828511 | Multiple Myelom... | Linvoseltamab | 18 Years - | Regeneron Pharmaceuticals | |
| BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma | NCT04271644 | Multiple Myelom... Neoplasm, Plasm... Multiple Myelom... | BCMA CAR-T cell... | 18 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma | NCT04036461 | Multiple Myelom... | CC-99712 BMS-986405 | 18 Years - | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
